Health knowledge made personal
Join this community!
› Share page:
Search posts:

Topical Antibiotic with Immune Stimulating Oligodeoxynucleotide Molecules to Speed Wound Healing

Posted Oct 21 2012 8:00pm

Description of Invention:
The present technology provides a mean of improving the activity of topical antibiotics. Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. But in eliminating bacteria in the wound, such antibiotics also eliminate the molecular signals present in bacterial DNA that stimulate to immune system's wound healing processes. Without these signals the rate of wound healing is diminished. It would be desirable for topical antibiotics to remove infectious bacteria but also provide the immune stimulating signals needed to promote and accelerate healing. The present formulation accomplishes these goals by supplementing the antibiotic formulation with immunostimulatory oligodeoxynucleotides (ODN). These ODN express the CpG motifs present in bacterial DNA and safely mimic the immune stimulation induced by bacterial DNA. The formulation may be applied directly to a wide variety of wounds to skin (such as traumatic, burn, or surgical wound), or the eyes (such as corneal abrasions) to effectively eliminate infection and stimulate rapid healing of the wound.

Topical antibiotic

Eliminates wound site bacteria while retaining immune stimulating properties that promote faster wound healing

Development Status:
  • Early-stage
  • In vivo data available (animal)

Dennis M Klinman (NCI)

Patent Status:
HHS, Reference No. E-294-2011/0
US, Application No. 61/639,688 filed 27 Apr 2012

Related Technologies:
US, Application No. 12/205,756 filed 05 Sep 2008, Reference No. E-328-2001/1

Relevant Publication:
  1. Ito H, et al. Antibiotics delay wound healing: an effect reversed by co-administering TLR7 and 9 ligands. Current Angiogenesis. 2012 Apr;1(1):46-51.
  2. Sato T, et al. [ PMID 20946144 ]
  3. Yamamoto M, et al. [ PMID 21421264 ]

Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize adding immunostimulatory CpG oligonucleotides to a topical antibiotic formulation to accelerate wound healing. For collaboration opportunities, please contact John Hewes, Ph.D. at .

For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5031
Fax: 301-402-0220

Ref No: 2487

Updated: 10/2012

Post a comment
Write a comment:

Related Searches